Provention Bio, Inc.
NASDAQ: PRVB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ashleigh W. Palmer
- Employees
- 174
- Headquarters
- Red Bank, United States
- IPO year
- 2018
- Market cap
- $2.4B
- Website
- https://www.proventionbio.com
Loading PRVB…
Loading profile data…Frequently asked questions about PRVB
What does Provention Bio, Inc. (PRVB) do?
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes...
Where does PRVB trade?
Provention Bio, Inc. (PRVB) trades on the NASDAQ Global Select.
What sector is PRVB in?
Provention Bio, Inc. (PRVB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Provention Bio, Inc.?
Ashleigh W. Palmer is the chief executive officer of Provention Bio, Inc. (PRVB).
Where is Provention Bio, Inc. headquartered?
Provention Bio, Inc. is headquartered in United States.
Does PRVB pay a dividend?
Provention Bio, Inc. (PRVB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PRVB go public?
Provention Bio, Inc. (PRVB) completed its initial public offering in 2018.